Document Detail


What is the optimum perioperative drug therapy following lower-extremity vein bypass surgery?
MedLine Citation:
PMID:  20006805     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
While endoluminal procedures are now commonly done for symptomatic peripheral arterial disease, vein bypass remains the gold standard for revascularization. Lower extremity vein bypass procedure success is dependent on patient factors, surgical judgment and technique, including use of medications. Cardioprotective medications have proven efficacy to decrease morbidity and mortality, but their use to improve graft patency is less well known. We review the up to date use of medications with known vascular effects that may promote graft success, as well as decrease cardiovascular events in this high risk patient group.
Authors:
Peter Henke
Related Documents :
3775465 - Coagulase-negative staphylococcal endocarditis: a view from the community hospital.
17022195 - Greater palatine island axial pattern flap for repair of oronasal fistula related to eo...
6403785 - Complications of co2 laser surgery of the larynx.
12149175 - Neutropenic enterocolitis.
9024865 - Ultrastructure of sensory endings in diplostomum pseudospathaceum niewiadomska, 1984 ce...
16881945 - Low literacy impairs comprehension of prescription drug warning labels.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in vascular surgery     Volume:  22     ISSN:  1558-4518     ISO Abbreviation:  Semin Vasc Surg     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-17     Completed Date:  2010-06-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8809602     Medline TA:  Semin Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  245-51     Citation Subset:  IM    
Affiliation:
Section of Vascular Surgery, University of Michigan, Ann Arbor, MI, USA. henke@umich.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use
Anticoagulants / therapeutic use
Antihypertensive Agents / therapeutic use
Biological Markers / metabolism
Clinical Protocols
Graft Occlusion, Vascular / drug therapy*
Humans
Inflammation / metabolism
Leg / blood supply*
Perioperative Care
Peripheral Vascular Diseases / surgery*
Platelet Aggregation Inhibitors / therapeutic use
Vascular Patency*
Vascular Surgical Procedures / methods
Vasodilator Agents / therapeutic use
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Anticoagulants; 0/Antihypertensive Agents; 0/Biological Markers; 0/Platelet Aggregation Inhibitors; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hybrid procedures and distal origin grafts.
Next Document:  Detection of imminent vein graft occlusion: what is the optimal surveillance program?